Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 936 trials

Acute Brain Injury: Apomorphine and Psilocybin Study

We are exploring the safety of two medications in patients who are unresponsive in the ICU due to brain injury. The goal is to find effective doses while monitoring for any side effects.

Coma and Disorders of Consciousness3-6 monthsSafety phase (I)Investigational MedicinesNeurologyPsychiatry

Metastatic Breast Cancer: Treatment Combinations Study

We are evaluating the effectiveness and safety of various treatment combinations for patients with metastatic breast cancer. This study aims to find better options for managing the disease.

Metastatic Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: BMS-986340 Treatment Study

We are testing a new treatment called BMS-986340, both alone and with other medications, for people with advanced solid tumors. The goal is to assess its safety and how well it may work against cancer.

Advanced Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Myeloma: JNJ-79635322 Study

We are testing a new medication for individuals with relapsed or refractory multiple myeloma or previously treated AL amyloidosis. The goal is to see how safe and effective this treatment is in humans.

Relapsed or Refractory Multiple MyelomaPreviously Treated AL Amyloidosis1-2 yearsSafety phase (I)HematologyOncology

Progressive Pulmonary Fibrosis: FAPI-PET Imaging Study

We are exploring if a special imaging method can help identify the type of lung condition in patients with progressive pulmonary fibrosis. This may improve how we understand and treat their disease.

Progressive Pulmonary Fibrosis3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPulmonology

Prostate Cancer: Saruparib and Darolutamide Study

We are examining the effects of Saruparib and Darolutamide, both alone and together, in men with newly diagnosed prostate cancer. This research aims to understand how these treatments may impact patients before surgery.

Newly Diagnosed Prostate Cancer6-12 monthsSafety phase (I)OncologyUrology

Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Solid Tumors: Investigational Drug THE-0504

We are assessing the safety and tolerability of THE-0504 for patients with solid tumors. This trial aims to understand how well the drug is tolerated by participants.

Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Non-Small Cell Lung Cancer: BAY2927088 Study

We are testing a new treatment for patients with advanced NSCLC who have mutations in the EGFR and/or HER2 genes. This study aims to explore its effects on cancer progression.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyPulmonology

Severe Autoimmune Diseases: CD19-targeted CAR T Cell Therapy

We are testing a new CAR T cell treatment for individuals with severe autoimmune diseases that haven't responded to other therapies. The goal is to see if this approach is safe and how well it works.

Idiopathic Inflammatory MyopathyRheumatoid ArthritisSystemic Sclerosis>2 yearsSafety phase (I)Infectious DiseasesRheumatology

DS-1103a: New Combination Therapy Study

We are testing a new combination therapy for patients with specific health conditions. This study aims to understand its safety and effectiveness in humans for the first time.

HER2 Positive Breast Cancer>2 yearsSafety phase (I)Oncology

Prostate Cancer: RO7656594 Treatment Study

We are evaluating a new medication for patients with advanced or metastatic prostate cancer. The study focuses on its safety and how the body handles the drug.

Advanced or Metastatic Prostate Cancer>2 yearsSafety phase (I)Oncology

Advanced Prostate Cancer: JNJ-87189401 and JNJ-78278343

We are exploring the safety of a new combination of medications for patients with advanced prostate cancer. This study aims to find out how well these drugs work together.

Advanced Prostate Cancer>2 yearsSafety phase (I)Oncology

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Advanced Solid Tumors: T3P-Y058-739 Treatment

We are testing a new genetically-modified bacterium for patients with advanced solid tumors. This study aims to explore its safety and potential benefits in treating cancer.

Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

RA0127: First-in-Human Safety Study

We are testing a new drug, RA0127, in healthy young volunteers to see if it is safe and well-tolerated. This study will help us understand how the drug affects people before further testing.

Prevention of Gram-negative Bacterial InfectionsSafety phase (I)Infectious Diseases